Company intelligence / Profile preview
Jiangsu BioJeTay Biotechnology
Wuxi, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Jiangsu BioJeTay Biotechnology is conducting a Phase 3 clinical study of STSP-0601, a monoclonal antibody targeting coagulation factor XIIa, for patients with hemophilia who have developed inhibitors. Clinical efficacy and safety are being evaluated in a multicenter, open-label study initiated in April 2025[4].
- Therapeutic areas
- Hematology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Jiangsu BioJeTay Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jiangsu BioJeTay Biotechnology.